Tosato Marianna, Asti Mattia
Radiopharmaceutical Chemistry Section, Nuclear Medicine Unit, AUSL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Pharmaceuticals (Basel). 2023 Jun 26;16(7):929. doi: 10.3390/ph16070929.
The interest in silver radioisotopes of medical appeal (silver-103, silver-104m,g and silver-111) has been recently awakened by the versatile nature of their nuclear decays, which combine emissions potentially suitable for non-invasive imaging with emissions suited for cancer treatment. However, to trigger their in vivo application, the production of silver radioisotopes in adequate amounts, and with high radionuclidic purity and molar activity, is a key prerequisite. This review examines the different production routes of silver-111, silver-103 and silver-104m,g providing a comprehensive critical overview of the separation and purification strategies developed so far. Aspects of quality (radiochemical, chemical and radionuclidic purity) are also emphasized and compared with the aim of pushing towards the future implementation of this theranostic triplet in preclinical and clinical contexts.
近期，具有医学应用价值的银放射性同位素（银 - 103、银 - 104m,g和银 - 111）因其核衰变的多功能特性重新引发了人们的兴趣，这些核衰变将潜在适用于非侵入性成像的发射与适用于癌症治疗的发射相结合。然而，要推动它们在体内的应用，以足够的量、高放射性核素纯度和摩尔活度生产银放射性同位素是一个关键前提条件。本综述考察了银 - 111、银 - 103和银 - 104m,g的不同生产路线，对迄今为止开发的分离和纯化策略进行了全面的批判性概述。还强调了质量方面（放射化学纯度、化学纯度和放射性核素纯度），并将其与推动这一治疗诊断三联体在临床前和临床环境中未来应用的目标进行了比较。
